Oral Presentation Australian Society for Microbiology Annual Scientific Meeting 2019

Rapid Response Pipeline for Stabilized Subunit Vaccines (#11)

Keith Chappell 1 , Paul Young 1
  1. School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia

The University of Queensland has recently received $14.7M in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to establish a rapid response vaccine pipeline. This project brings together unique proprietary recombinant technology for generating stabilized subunit vaccines (the molecular clamp), a highly skilled team from some of Australia’s leading scientific organizations and world-class facilities.

Molecular clamp is a broadly applicable platform technology that facilitates expression of recombinant viral glycoproteins in subunit form without loss of native antigenicity. The molecular clamp imparts superior stability over alternative trimerization domains, efficiently stabilizing soluble viral fusion proteins in their native trimeric 'pre-fusion' form. This form is equivalent to that expressed on the virion surface and the principle target for a protective neutralizing antibody response. Through stabilization of the pre-fusion form, the molecular clamp promotes the production of highly neutralizing and broadly cross-reactive antibodies. Importantly, the molecular clamp does not required prior knowledge of a proteins quaternary structure.

The goal of this project is to establish a holistic and robust pipeline to rapidly generate novel subunit vaccines purely from sequence information. Within this pipeline, pre-clinical development, including the generation of evidence for safety and immunogenicity in animal models, is to be completed within a 16 week window allowing candidate vaccines to then progress directly into Phase I clinical trials. Phase I trials, including regulatory approval, patient immunization and analysis of safety and immunogenicity will be completed within 10 weeks (week 17-26 of the pipeline). As part of the project, large-scale manufacture of >200,000 vaccine doses will be completed within a further 8 weeks. Vaccine produced through this pipeline will therefore be available for rapid deployment and provide the best possible opportunity to counter emerging viral epidemics.